What happened with SOLV today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Hospitals, clinics and dental practices buy Solventum’s products to treat wounds, prevent infection, perform surgery and provide dental care. Its MedSurg business supplies most of its revenue, with products such as advanced wound dressings and materials that secure intravenous lines. Dental Solutions is a smaller business supplying materials for tooth restoration and products for orthodontic treatment. Solventum sells directly to healthcare providers and through distributors.
It also sells software and services through Health Information Systems. Products including Solventum 360 Encompass help healthcare providers document care, assign billing codes and manage reimbursement. This is a separate source of income from its physical healthcare products.
The business depends partly on the insurance and government reimbursement available to its customers, which affects product choices and demand. It also relies on 3M as the sole supplier of certain inputs used in products that generate a substantial share of revenue; Solventum has not identified suitable substitutes and cannot make those materials itself. Selling its products requires maintaining regulatory approvals, and promotional claims are limited to authorized uses. Agreements with 3M also restrict some uses of licensed technology and certain products, customers or end users.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Solventum’s results depend heavily on wound-care and surgical-supply demand, but important wound-care rivals Mölnlycke, Convatec and Coloplast are missing from this list.
Smith+Nephew competes with Solventum for healthcare customers’ spending on advanced wound dressings and is its primary challenger in negative-pressure wound therapy. Watch its wound-device business for signs of competitive pressure on Solventum’s wound-care sales.
Solventum depends on 3M to manufacture products under agreements made at the separation, and 3M’s mark-ups raise Solventum’s costs and squeeze margins. Watch changes to those supply arrangements: a full year of mark-ups helped lower Solventum’s MedSurg margin in 2025.
BD competes with Solventum for healthcare institutions’ purchases of infection-prevention and surgical supplies. Its sales of those products offer a read on the hospital demand both businesses serve.
Medline Inc. competes with Solventum in infection-prevention and surgical supplies sold to hospitals and other care facilities. Watch demand for Medline’s own-brand medical-surgical products, rather than its sales of third-party supplies, for the closer comparison.
STERIS competes with Solventum for healthcare facilities’ spending on infection-prevention and sterilization-related products. Watch its healthcare consumables demand: STERIS says more medical procedures support demand for many of its offerings.
Envista Holdings Corporation competes with Solventum for dental practices’ purchases of tooth-restoration consumables and orthodontic products. Its restorative and orthodontic sales are the relevant lines to watch, rather than its imaging equipment business.
Dentsply Sirona competes with Solventum for dental professionals’ spending on dental and orthodontic products. Its dental-product demand offers a comparison for Solventum’s Dental Solutions business, unlike its urological and enterological consumables.
Waystar Holding Corp. competes with Solventum by selling healthcare providers software that helps them collect revenue and obtain accurate reimbursement. Watch adoption of its claims and revenue-capture tools alongside Solventum 360 Encompass, whose wider adoption supported Solventum’s software growth in 2025.
ICU Medical competes with Solventum for hospitals’ purchases of temperature-management and infection-prevention supplies. Its temperature-management products provide a closer comparison for Solventum than its broader infusion-pump business.
Fortive’s Advanced Healthcare Solutions business competes with Solventum in products that help healthcare customers sterilize instruments and prevent infection. Watch that business’s sterilization offerings, not Fortive’s industrial instruments, for the relevant demand signal.
Integra LifeSciences competes with Solventum in surgical biomaterials and wound-care technologies used by healthcare providers to repair tissue. Its Tissue Technologies business is the line to watch for this overlap, rather than its larger neurosurgery business.
Align Technology competes for orthodontic spending by selling Invisalign clear aligners to dental professionals, against Solventum’s aligners and traditional orthodontic products. Watch its clear-aligner sales alongside Solventum’s traditional orthodontic sales, which declined in 2025.
MiMedx Group, Inc competes for providers’ wound-treatment choices with grafts made from donated human birth tissue and animal tissue, against Solventum’s tissue matrices and other advanced treatments. Watch adoption of those grafts in wound care, where reimbursement and clinical protocols can influence which treatment providers choose.
Cardinal Health competes with Solventum through its own-brand medical-surgical products sold to healthcare providers, not through its distribution business. Watch those branded products for pressure on Solventum’s infection-prevention and surgical-supply sales, rather than Cardinal’s pharmaceutical distribution revenue.
3M Company earningsMMM
If 3M’s report discloses changes to supply arrangements or input costs, readers can gauge whether they are easing Solventum’s MedSurg cost pressure.
Look for any disclosure about 3M’s supply arrangements with Solventum or related costs; 3M may not report the mark-ups Solventum actually pays. If 3M describes easing terms or costs, margins on Solventum products that rely on this supply may have more room; if mark-ups or cost pressure persist, MedSurg margins remain squeezed. Without relevant disclosure, this report says little about Solventum’s costs.
MiMedx Group, Inc earningsMDXG
MiMedx’s report will show whether providers are adopting its tissue grafts, a signal of competition for Solventum’s advanced wound-care products.
Look at sales or adoption of MiMedx’s tissue-graft business alongside the treatment choices facing Solventum’s advanced wound-care products. Rising adoption would mean providers are choosing this alternative more often, potentially increasing competition for Solventum; weak adoption would mean less pressure from this product type, but would not establish demand for Solventum’s own products.
Align Technology Inc earningsALGN
Align Technology’s report will show whether demand for clear aligners is shifting orthodontic spending away from traditional products that compete with Solventum.
Compare the direction of Align’s clear-aligner sales with Solventum’s traditional orthodontic sales. Stronger aligner sales alongside weaker traditional-product sales would point to spending shifting toward aligners and greater substitution pressure on Solventum; weak aligner sales would mean less pressure from this alternative, but Solventum’s own demand would still need to be assessed.
Waystar Holding Corp. earningsWAY
Waystar’s report will show provider adoption of its claims and revenue-capture software, a competitive read for Solventum’s health information systems business.
Compare adoption of Waystar’s claims and revenue-capture tools with adoption trends for Solventum products such as 360 Encompass. Stronger Waystar adoption shows providers are buying this kind of reimbursement and revenue-management software, intensifying competition for Solventum’s software spending; weaker adoption softens that competitive signal but does not determine Solventum’s own sales.
Medline Inc. earningsMDLN
Sales of Medline’s own-brand medical-surgical products will show hospital demand in infection-prevention and surgical supplies that compete with Solventum’s MedSurg business.
Focus on sales of Medline’s own-brand medical-surgical products, not its distribution of third-party products. Stronger sales would indicate firmer hospital demand or purchasing in this category, supporting the market for Solventum’s MedSurg products while also showing active competition; weaker sales would suggest that spending by shared customers may be softening and Solventum’s related products face demand pressure.
Envista Holdings Corporation earningsNVST
Envista’s restorative-product sales will show the strength of dental-practice demand for products that compete with Solventum’s Dental Solutions.
Focus on Envista’s restorative-product sales and compare them with demand for Solventum’s restorative products. Stronger sales would indicate firmer practice purchasing, but also more competition for that spending; weaker sales would suggest demand in the shared restorative category may be slowing, rather than a problem unique to Solventum.
Solventum Corporation earningsThis company
Solventum’s report will show whether sales growth in MedSurg, Dental Solutions and Health Information Systems is holding up each segment’s profit margin.
Compare sales growth with segment operating margins, especially the cost pressure in MedSurg and Dental Solutions and the pricing and product mix in Health Information Systems. If sales grow and margins hold or rise, growth is not being eaten up by costs; if sales grow but margins fall, costs are running ahead of revenue. Segment margins give a clearer read on operations than total operating income, which was affected by a business-sale gain.
